Capacidad predictora y diferencial del mismatch negativity en pacientes con esquizofrenia y consumidores de cannabis
Barra lateral del artículo
Descargas
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Contenido principal del artículo
Resumen
El mismatch negativity (MMN) es un potencial relacionado con eventos que se ha encontrado alterado en esquizofrenia y consumo de cannabis. Objetivo: evaluar la capacidad predictora y diferencial del MMN en esquizofrenia y consumidores de cannabis. Método: en 23 consumidores de cannabis con esquizofrenia (ESQ+CN), 23 pacientes sin consumo (ESQ) y 21 consumidores de cannabis (CN) se obtuvo el potencial MMN en un EEG de 32 canales. Resultados: para la condición duración, la amplitud del MMNd de ESQ+CN y ESQ fue menor en comparación con CN, mientras que para frecuencia (MMNf) ESQ fue menor que ESQ+CN y CN. No se encontraron diferencias en latencia. En la curva ROC la amplitud del MMNd discriminó el 71.2% de los participantes con esquizofrenia (p =.016) y el MMNf el 82.6% (p = <.001). Conclusiones: el MMNf está asociado con esquizofrenia, mientras el MMNd podría ser útil en el seguimiento de los consumidores de cannabis.
Citas
Babor, T. F., Higgins-Biddle, J. C., Saunders, J. B., & Monteiro, M. G. (2001). Cuestionario de Identificación de los Transtornos debidos al Consumo de Alcohol. Pautas para su utilización en atención primaria. Ginebra: Organización Mundial de la Salud.
Burgueño, M., García-Bastos, J., & González-Buitrago, J. (1995). Las curvas ROC en la evaluación de las pruebas diagnósticas. Med Clin (Barc), 104(17), 661-670.
De Luca, M. A., Di Chiara, G., Cadoni, C., Lecca, D., Orsolini, L., Papanti, D., … Schifano, F. (2017). Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update. CNS & Neurological Disorders Drug Targets, 16(5), 598-609. https://doi.org/10.2174/1871527316666170413113246
D’Souza, D. C., Sewell, R. A., & Ranganathan, M. (2009). Cannabis and psychosis/schizophrenia: Human studies. European Archives of Psychiatry and Clinical Neuroscience, 259(7), 413-431. https://doi.org/10.1007/s00406-009-0024-2
Duncan, C. C., Barry, R. J., Connolly, J. F., Fischer, C., Michie, P. T., Näätänen, R., … Van Petten, C. (2009). Event-related potentials in clinical research: Guidelines for eliciting, recording, and quantifying mismatch negativity, P300, and N400. Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology, 120(11), 1883-1908. https://doi.org/10.1016/j.clinph.2009.07.045
Erickson, M. A., Ruffle, A., & Gold, J. M. (2016). A Meta-Analysis of Mismatch Negativity in Schizophrenia: From Clinical Risk to Disease Specificity and Progression. Biological Psychiatry, 79(12), 980-987. https://doi.org/10.1016/j.biopsych.2015.08.025
Foti, D. J., Kotov, R., Guey, L. T., & Bromet, E. J. (2010). Cannabis Use and the Course of Schizophrenia: 10-Year Follow-Up After First Hospitalization. American Journal of Psychiatry, 167(8), 987-993. https://doi.org/10.1176/appi.ajp.2010.09020189
Gallinat, J., Rentzsch, J., & Roser, P. (2012). Neurophysiological effects of cannabinoids: Implications for psychosis research. Current Pharmaceutical Design, 18(32), 4938-4949. https://doi.org/10.2174/138161212802884582
Garrido, M. I., Kilner, J. M., Stephan, K. E., & Friston, K. J. (2009). The mismatch negativity: A review of underlying mechanisms. Clinical Neurophysiology, 120(3), 453-463. https://doi.org/10.1016/j.clinph.2008.11.029
Greenwood, L., Broyd, S. J., Croft, R., Todd, J., Michie, P. T., Johnstone, S., … Solowij, N. (2014). Chronic Effects of Cannabis Use on the Auditory Mismatch Negativity. Biological Psychiatry, 75(6), 449-458. https://doi.org/10.1016/j.biopsych.2013.05.035
Griffith-Lendering, M. F. H., Wigman, J. T. W., Prince van Leeuwen, A., Huijbregts, S. C. J., Huizink, A. C., Ormel, J., … Vollebergh, W. A. M. (2013). Cannabis use and vulnerability for psychosis in early adolescence-a trials study: Cannabis use and vulnerability for psychosis. Addiction, 108(4), 733-740. https://doi.org/10.1111/add.12050
Groppe, D. M., Urbach, T. P., & Kutas, M. (2011). Mass univariate analysis of event-related brain potentials/fields I: A critical tutorial review. Psychophysiology, 48(12), 1711-1725. https://doi.org/10.1111/j.1469-8986.2011.01273.x
Haigh, S. M., Coffman, B. A., & Salisbury, D. F. (2017). Mismatch Negativity in First-Episode Schizophrenia: A Meta-Analysis. Clinical EEG and Neuroscience, 48(1), 3-10. https://doi.org/10.1177/1550059416645980
Hermens, D. F., Lubman, D. I., Ward, P. B., Naismith, S. L., & Hickie, I. B. (2009). Amphetamine psychosis: A model for studying the onset and course of psychosis. The Medical Journal of Australia, 190(4 Suppl), S22-25. Retrieved from https://www.mja.com.au/system/files/issues/190_04_160209/her10820_fm.pdf
Javitt, D. C., Spencer, K. M., Thaker, G. K., Winterer, G., & Hajós, M. (2008). Neurophysiological biomarkers for drug development in schizophrenia. Nature Reviews. Drug Discovery, 7(1), 68-83. https://doi.org/10.1038/nrd2463
Khokhar, J. Y., Dwiel, L. L., Henricks, A. M., Doucette, W. T., & Green, A. I. (2018). The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophrenia Research, 194, 78-85. https://doi.org/10.1016/j.schres.2017.04.016
Kuepper, R., Morrison, P. D., van Os, J., Murray, R. M., Kenis, G., & Henquet, C. (2010). Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophrenia Research, 121(1-3), 107-117. https://doi.org/10.1016/j.schres.2010.05.031
Lautenschlager, G. J., & Flaherty, V. L. (1990). Computer administration of questions: More desirable or more social desirability? Journal of Applied Psychology, 75(3), 310-314. https://doi.org/10.1037/0021-9010.75.3.310
Light, G. A., & Makeig, S. (2015). Electroencephalographic biomarkers of psychosis: Present and future. Biological Psychiatry, 77(2), 87-89. https://doi.org/10.1016/j.biopsych.2014.11.002
Light, G. A., Williams, L. E., Minow, F., Sprock, J., Rissling, A., Sharp, R., … Braff, D. L. (2010). Electroencephalography (EEG) and Event-Related Potentials (ERPs) with Human Participants. In J. N. Crawley, C. R. Gerfen, M. A. Rogawski, D. R. Sibley, P. Skolnick, & S. Wray (Eds.), Current Protocols in Neuroscience. Hoboken, NJ, USA: John Wiley & Sons, Inc. https://doi.org/10.1002/0471142301.ns0625s52
Lopez-Calderon, J., & Luck, S. J. (2014). ERPLAB: An open-source toolbox for the analysis of event-related potentials. Frontiers in Human Neuroscience, 8, 213. https://doi.org/10.3389/fnhum.2014.00213
Murray, R. M., Morrison, P. D., Henquet, C., & Di Forti, M. (2007). Cannabis, the mind and society: The hash realities. Nature Reviews. Neuroscience, 8(11), 885-895. https://doi.org/10.1038/nrn2253
Näätänen, R. (2003). Mismatch negativity: Clinical research and possible applications. International Journal of Psychophysiology: Official Journal of the International Organization of Psychophysiology, 48(2), 179-188. https://doi.org/10.1016/S0167-8760(03)00053-9
Observatorio Interamericano de Drogas OAS CICAD. (2011). Protocolo de la encuesta sobre drogas en hogares. Instrumentos para la realización de los Estudios Nacionales de Drogas en Población General (pp. 1-80). Sistema Interamericano de Datos Uniformes. Recuperado de http://www.cicad.oas.org/oid/protocols/1_PROTOCOLO_Encuesta_Hogares_Julio_2011.pdf
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016). Schizophrenia. The Lancet, 388(10039), 86-97. https://doi.org/10.1016/S0140-6736(15)01121-6
Palacio, C. A., García, J., Arbeláez, M. P., Sánchez, R., Aguirre, B., Garcés, I. C., … Ospina, J. (2004). [Validation of the Diagnostic Interview for Genetic Studies (DIGS) in Colombia]. Biomédica: Revista Del Instituto Nacional De Salud, 24(1), 56-62. Recuperado de http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-41572004000100008&lng=en&nrm=iso&tlng=es
Pesa, N., Hermens, D. F., Battisti, R. A., Kaur, M., Hickie, I. B., & Solowij, N. (2012). Delayed preattentional functioning in early psychosis patients with cannabis use. Psychopharmacology, 222(3), 507-518. https://doi.org/10.1007/s00213-012-2676-2
Pope, C., Mechoulam, R., & Parsons, L. (2010). Endocannabinoid signaling in neurotoxicity and neuroprotection. Neurotoxicology, 31(5), 562-571. https://doi.org/10.1016/j.neuro.2009.12.002
Rabin, R. A., Zakzanis, K. K., & George, T. P. (2011). The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. Schizophrenia Research, 128(1-3), 111-116. https://doi.org/10.1016/j.schres.2011.02.017
Rentzsch, J., Buntebart, E., Stadelmeier, A., Gallinat, J., & Jockers-Scherübl, M. C. (2011). Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects. Schizophrenia Research, 130(1-3), 222-227. https://doi.org/10.1016/j.schres.2011.05.011
Roser, P., Pichler, E.-M., Habermeyer, B., Kawohl, W., & Juckel, G. (2019). Impact of Chronic Cannabis Use on Auditory Mismatch Negativity Generation in Schizophrenia Patients. Pharmacopsychiatry, 52(3), 126-133. https://doi.org/10.1055/a-0573-9866
Sarne, Y., Asaf, F., Fishbein, M., Gafni, M., & Keren, O. (2011). The dual neuroprotective-neurotoxic profile of cannabinoid drugs. British Journal of Pharmacology, 163(7), 1391-1401. https://doi.org/10.1111/j.1476-5381.2011.01280.x
Schaefer, J., Giangrande, E., Weinberger, D. R., & Dickinson, D. (2013). The global cognitive impairment in schizophrenia: Consistent over decades and around the world. Schizophrenia research, 150(1), 42-50. https://doi.org/10.1016/j.schres.2013.07.009
Schnell, T., Koethe, D., Daumann, J., & Gouzoulis-Mayfrank, E. (2009). The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology, 205(1), 45-52. https://doi.org/10.1007/s00213-009-1512-9
Umbricht, D., & Krljes, S. (2005). Mismatch negativity in schizophrenia: A meta-analysis. Schizophrenia Research, 76(1), 1-23. https://doi.org/10.1016/j.schres.2004.12.002
Wechsler, D., Meng, Y., Martínez, I., & Zhu, J. (2014). WAIS-IV: Escala Wechsler de Inteligencia para Adultos-IV. El Manual Moderno.
Woods, S. W. (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. The Journal of Clinical Psychiatry, 64(6), 663-667.
Yücel, M., Bora, E., Lubman, D. I., Solowij, N., Brewer, W. J., Cotton, S. M., … Pantelis, C. (2012). The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin, 38(2), 316-330. https://doi.org/10.1093/schbul/sbq079
Zamora, R. C., Von Seggern, B., Toledo, R., & Harrell, E. H. (1990). El inventario de Edimburgo: Evaluación de la lateralidad cerebral en una población mexicana. Salud Mental, 13(2), 11-17. Recuperado de http://132.247.16.48/index.php/salud_mental/article/view/404